|
|
|
|
| LEADER |
00000cam a2200000 c 4500 |
| 001 |
1736040006 |
| 003 |
DE-627 |
| 005 |
20240510204059.0 |
| 007 |
tu |
| 008 |
201020s2020 gw ||||| m 00| ||ger c |
| 035 |
|
|
|a (DE-627)1736040006
|
| 035 |
|
|
|a (DE-599)KXP1736040006
|
| 035 |
|
|
|a (OCoLC)1225625613
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rda
|
| 041 |
|
|
|a ger
|
| 044 |
|
|
|c XA-DE-BW
|
| 084 |
|
|
|a 33
|2 sdnb
|
| 100 |
1 |
|
|a Schmitt, Lara-Marie
|d 1991-
|e VerfasserIn
|0 (DE-588)1184917698
|0 (DE-627)1663770115
|4 aut
|
| 245 |
1 |
0 |
|a Alectinib als Behandungsstrategie in Anaplastic lymphoma kinase-exprimierenden Glioblastomzellen
|b Biomarker des Inhibitors, Wirkmechanismus und Resistenzentstehung
|c vorgelegt von Lara-Marie Schmitt ; Doktorvater: Prof. Dr. med. Wolfgang Wick
|
| 264 |
|
1 |
|a Heidelberg
|c 2020
|
| 300 |
|
|
|a 115 Blätter
|b Illustrationen, Diagramme
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 502 |
|
|
|b Dissertation
|c Ruprecht-Karls-Universität Heidelberg
|d 2020
|
| 583 |
1 |
|
|a Archivierung/Langzeitarchivierung gewährleistet
|f DISS
|x XA-DE-BW
|2 pdager
|5 DE-16
|
| 655 |
|
7 |
|a Hochschulschrift
|0 (DE-588)4113937-9
|0 (DE-627)105825778
|0 (DE-576)209480580
|2 gnd-content
|
| 700 |
1 |
|
|a Wick, Wolfgang
|d 1970-
|e AkademischeR BetreuerIn
|0 (DE-588)120297736
|0 (DE-627)080586929
|0 (DE-576)186221320
|4 dgs
|
| 710 |
2 |
|
|a Universität Heidelberg
|e Grad-verleihende Institution
|0 (DE-588)2024349-2
|0 (DE-627)102161488
|0 (DE-576)191769517
|4 dgg
|
| 751 |
|
|
|a Heidelberg
|0 (DE-588)4023996-2
|0 (DE-627)106300814
|0 (DE-576)208952578
|4 uvp
|
| 951 |
|
|
|a BO
|
| 992 |
|
|
|a 20201021
|
| 993 |
|
|
|a Thesis
|
| 994 |
|
|
|a 2020
|
| 998 |
|
|
|g 1184917698
|a Schmitt, Lara-Marie
|m 1184917698:Schmitt, Lara-Marie
|d 50000
|d 51001
|e 50000PS1184917698
|e 51001PS1184917698
|k 0/50000/
|k 1/50000/51001/
|p 1
|x j
|y j
|
| 999 |
|
|
|a KXP-PPN1736040006
|e 3783538556
|
| BIB |
|
|
|a Y
|
| JSO |
|
|
|a {"recId":"1736040006","physDesc":[{"noteIll":"Illustrationen, Diagramme","extent":"115 Blätter"}],"noteThesis":["Dissertation. - Ruprecht-Karls-Universität Heidelberg. - 2020"],"name":{"displayForm":["vorgelegt von Lara-Marie Schmitt ; Doktorvater: Prof. Dr. med. Wolfgang Wick"]},"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"2020","publisherPlace":"Heidelberg"}],"person":[{"display":"Schmitt, Lara-Marie","role":"aut","given":"Lara-Marie","family":"Schmitt"},{"display":"Wick, Wolfgang","role":"dgs","given":"Wolfgang","family":"Wick"}],"corporate":[{"display":"Universität Heidelberg","role":"dgg"}],"id":{"eki":["1736040006"]},"title":[{"title_sort":"Alectinib als Behandungsstrategie in Anaplastic lymphoma kinase-exprimierenden Glioblastomzellen","title":"Alectinib als Behandungsstrategie in Anaplastic lymphoma kinase-exprimierenden Glioblastomzellen","subtitle":"Biomarker des Inhibitors, Wirkmechanismus und Resistenzentstehung"}],"type":{"bibl":"thesis"},"language":["ger"]}
|
| SRT |
|
|
|a SCHMITTLARALECTINIBA2020
|
